<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02405793</url>
  </required_header>
  <id_info>
    <org_study_id>MEL2-14-05</org_study_id>
    <nct_id>NCT02405793</nct_id>
  </id_info>
  <brief_title>Meloxicam SoluMatrix® Capsules vs Meloxicam Tablets to Treat Osteoarthritis Pain</brief_title>
  <official_title>A Phase 2b, Multicenter, Randomized, Single Blind, Fixed Dose, Parallel Group Study to Evaluate the Efficacy and Safety of Meloxicam SoluMatrix® [Test] Capsules and Meloxicam Tablets in Patients With Pain Due to Osteoarthritis of the Knee or Hip</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Iroko Pharmaceuticals, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Iroko Pharmaceuticals, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of a low dose and a high
      dose of Meloxicam SoluMatrix® Capsules versus Meloxicam Tablets for the treatment of pain due
      to osteoarthritis of the knee or hip.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Internal business decision not to move forward with study
  </why_stopped>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Week 6 After Trial Entry in Osteoarthritis Pain Measured Using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score.</measure>
    <time_frame>Baseline to Week 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 6 After Trial Entry in Osteoarthritis Function Measured Using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Function Subscale Score.</measure>
    <time_frame>Baseline to Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 6 After Trial Entry in Osteoarthritis Stiffness Measured Using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale Score.</measure>
    <time_frame>Baseline to Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 6 After Trial Entry in Osteoarthritis Symptoms Measured Using the Total Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Score.</measure>
    <time_frame>Baseline to Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Pre-dose to 2 Hours Post-dose in Pain Intensity as Measured by the Numerical Pain Rating Scale on Day 3.</measure>
    <time_frame>2 hours after dosing on Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Pre-dose to 2 Hours Post-dose in Pain Intensity as Measured by the Numerical Pain Rating Scale on Day 14.</measure>
    <time_frame>2 hours after dosing on Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Pre-dose to 2 Hours Post-dose in Morning Stiffness Severity as Measured by the Numerical Rating Scale on Day 3.</measure>
    <time_frame>2 hours after dosing on Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Pre-dose to 2 Hours Post-dose in Morning Stiffness Severity as Measured by the Numerical Rating Scale on Day 14.</measure>
    <time_frame>2 hours after dosing on Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change</measure>
    <time_frame>Baseline to Week 6/Early Termination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Change</measure>
    <time_frame>Baseline to Week 6/Early Termination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Rescue Medication Taken by Each Subject</measure>
    <time_frame>Baseline to Week 6/Early Termination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Discontinuations Due to Lack of Efficacy at Week 6</measure>
    <time_frame>Baseline to Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responders with at Least a 10-mm Improvement in Mean Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Week 6.</measure>
    <time_frame>Baseline to Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Meloxicam SoluMatrix Capsules low dose, Meloxicam SoluMatrix Capsules high dose, and Meloxicam Tablets as Assessed by the Incidence of Adverse Events From Baseline to Week 6 or Early Termination</measure>
    <time_frame>Baseline to Week 6/Early Termination</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Meloxicam low dose test capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Meloxicam SoluMatrix Capsules - low dose QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Meloxicam high dose test capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Meloxicam SoluMatrix Capsules - high dose QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Meloxicam tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Meloxicam Tablets QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meloxicam Test Capsules</intervention_name>
    <arm_group_label>Meloxicam low dose test capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meloxicam Test Capsules</intervention_name>
    <arm_group_label>Meloxicam high dose test capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meloxicam Tablets</intervention_name>
    <arm_group_label>Meloxicam tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary diagnosis of Functional Class I-III osteoarthritis (OA) of the hip or knee

          -  Chronic user of nonsteroidal anti-inflammatory drugs (NSAIDs) and/or acetaminophen for
             OA pain

          -  Discontinued all analgesic therapy at Screening

          -  For women of childbearing potential: a woman who is not pregnant and not nursing, and
             who is practicing an acceptable method of birth control

          -  Ability to ambulate

        Exclusion Criteria:

          -  History of allergic reaction or clinically significant intolerance to acetaminophen,
             aspirin, or any NSAIDs, including meloxicam

          -  Requires regular (more than 2 doses per week) use of opioid or opioid combination
             products to control OA pain of the knee or hip

          -  Clinically significant unstable cardiac, respiratory, neurological, immunological,
             hematological, or renal disease

          -  Significant difficulties swallowing capsules/tablets or unable to tolerate oral
             medication

          -  Previous participation in another clinical study of Meloxicam Capsules or received any
             investigational drug or device or investigational therapy within 30 days before
             Screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2015</study_first_submitted>
  <study_first_submitted_qc>March 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2015</study_first_posted>
  <last_update_submitted>July 8, 2015</last_update_submitted>
  <last_update_submitted_qc>July 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meloxicam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

